Sheila Garcia-Santana, MD
Ophthalmology · Charlotte, NCNPI 1275760092
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,402 of the $2,935 with a category attached, or 81.8%. It is spread thinly across 19 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations.
Across 93 payments — averaging $31.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Notal Vision, Inc.$514
- Regeneron Healthcare Solutions, Inc.$426
- Genentech USA, Inc.$337
- AbbVie$254
- Apellis Pharmaceuticals, Inc.$212
- Coherus Oncology, Inc.$168
- plus $1K from 13 others
Across 6 payments — averaging $9449.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$57K
What the payments were for
- Speaking & faculty fees$47516%
- Travel & lodging$171%
- Food & beverage$2,40282%
- Education$411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Notal Vision, Inc. | 9 | $514 |
| Regeneron Healthcare Solutions, Inc. | 16 | $426 |
| Genentech USA, Inc. | 21 | $337 |
| AbbVie(2 entities) | 7 | $254 |
| Apellis Pharmaceuticals, Inc. | 6 | $212 |
| Coherus Oncology, Inc. | 1 | $168 |
| Alcon | 2 | $167 |
| Novartis | 7 | $160 |
| Astellas Pharma US Inc | 3 | $152 |
| ANI Pharmaceuticals, Inc. | 2 | $128 |
| Alimera Sciences, Inc. | 5 | $98 |
| Genentech, Inc. | 2 | $81 |
| Bausch & Lomb Americas Inc. | 4 | $79 |
| Biogen | 3 | $53 |
| Dompe US, Inc. | 1 | $24 |
| Oyster Point Pharma, Inc. | 1 | $24 |
| Aerie Pharmaceuticals, Inc. | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Amgen | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,935 in reported general payments places this provider in the 70th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 107 | $3,964 |
| Atropine Sulfate | 63 | $2,281 |
| MoxifloxacinMoxifloxacin Hcl | 63 | $1,182 |
| Latanoprost | 17 | $67 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Charlotte
- Thomas MundorfCharlotte$220K
- Charles BlotnickCharlotte$18K
- Adrian ElfersyCharlotte$13K
- Joseph KrugCharlotte$10K
- Royce SyracuseCharlotte$10K
- William HammondsCharlotte$9K
- Preeya GuptaRaleigh$1.8M
- Julie WoodwardDurham$1M
- Rajiv ShahWinston Salem$909K
- Lejla VajzovicDurham$681K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.